Nordic Life Science 1
TOP STORIES BUSINESS PA R T NER SHIP THE TWO COLL
ABORATORS WILL APPLY NANOFORM’S CESS TECHNOLOGY TO NEW CHEMICAL ENTITIES. UILDING ON AN existing relationship, this collaboration will utilize Nanoform’s CESS technology to Kaisa Helminen, CEO, Aiforia C OL L ABOR AT ION THIS PROJECT IS inspired by the donation of the entire brain and spinal column of a friend of a NeuroScience Associates (NSA) employee who died from ALS. NSA will use this donation to create a wholebrain reference dataset for ALS. NSA has comprehensive resources, and the technical capabilities and skills to prepare an entire, intact human brain hemisphere for research. But they needed much more powerful tools to support the analysis of the brain. “The artificial intelligence-powered platform from Aiforia enables us to view and 12 analyze the brain in ways that we were not able to before,” says Britt Massei, CEO and CFO, NSA Labs. “Their platform also allows us to store and manage the incredibly complex and large images produced from the brain samples.” “Aiforia’s mission is to provide global access to AI-powered image analysis directly to pathologists, scientists and healthcare professionals to enable them to make new discoveries and to understand disease mechanisms better,” says Kaisa Helminen, CEO, Aiforia. improve the bioavailability and solubility of selected early-development compounds, increasing the likelihood of drugs entering clinical development. “Materials science and particle engineering are vital to the success of pharmaceutical development and by utilizing nanoparticles in the range that Nanoform can produce we see great opportunity to simplify the formulation process, develop optimal products, and enable poorly soluble molecules to progress into the clinic. Producing tailored nanoparticles smaller than 200nm from solution, in a controlled and reproducible manner, with good yield and without the need for excipients is challenging to do by current pharmaceutical manufacturing techniques or processes. Now that Nanoform has a path to clinical development with their upcoming GMP facility we are excited to see how they can add value to Orion’s drug development products,” says Juha Kiesvaara, VP Global Pharmaceutical Research, Orion Corporation. NORDICLIFESCIENCE.ORG PHOTO ROB ORTHEN